These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12666431)

  • 1. [Characteristics of patients with osteopenia treated with glucocorticoids at the Osteoporosis Clinic of the Medical Faculty Hospital in Hradec Kralove].
    Müllerová H; Prixová M; Vlcek J; Mokrosová K; Rehorková P; Palicka V
    Vnitr Lek; 2003 Jan; 49(1):32-6. PubMed ID: 12666431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comment on the article "Characteristics of patients with osteopenia treated with glucocorticoids at the Osteoporosis Clinic of the Medical Faculty Hospital in Hradec Kralove"].
    Horák P
    Vnitr Lek; 2003 Jan; 49(1):10-1. PubMed ID: 12666422
    [No Abstract]   [Full Text] [Related]  

  • 3. Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men.
    Cruse LM; Valeriano J; Vasey FB; Carter JD
    J Clin Rheumatol; 2006 Oct; 12(5):221-5. PubMed ID: 17023807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment with corticosteroids, bone mineral density and risk of fractures].
    Rosa J
    Vnitr Lek; 2003 Jan; 49(1):12-4. PubMed ID: 12666423
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of osteoporosis self assessment tool for Asian (OSTA) and standard assessment in Menopause Clinic, Chiang Mai.
    Chaovisitsaree S; Namwongprom SN; Morakote N; Suntornlimsiri N; Piyamongkol W
    J Med Assoc Thai; 2007 Mar; 90(3):420-5. PubMed ID: 17427514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Glucocorticoid induced osteoporosis].
    Lange U; Müller-Ladner U
    Orthopade; 2007 Apr; 36(4):381-8; quiz 389-90. PubMed ID: 17665509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and predictors of fragility fractures in systemic lupus erythematosus.
    Yee CS; Crabtree N; Skan J; Amft N; Bowman S; Situnayake D; Gordon C
    Ann Rheum Dis; 2005 Jan; 64(1):111-3. PubMed ID: 15608308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vertebral fracture and bone mineral density in women receiving high dose glucocorticoids for treatment of autoimmune diseases.
    Kumagai S; Kawano S; Atsumi T; Inokuma S; Okada Y; Kanai Y; Kaburaki J; Kameda H; Suwa A; Hagiyama H; Hirohata S; Makino H; Hashimoto H
    J Rheumatol; 2005 May; 32(5):863-9. PubMed ID: 15868623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening and treatment of glucocorticoid-induced osteoporosis in rheumatoid arthritis patients in an urban multispecialty practice.
    Ledwich LJ; Clarke K
    J Clin Rheumatol; 2009 Mar; 15(2):61-4. PubMed ID: 19265346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention, diagnosis, and treatment of glucocorticoid induced osteoporosis by rheumatologists in a Latin-American city.
    Caballero-Uribe CV; Acosta-Velez JG; Hernandez-Ruiz EA; Andrade Rodado FM; Peñuela-Epalza M
    J Clin Rheumatol; 2008 Jun; 14(3):153-5. PubMed ID: 18525434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Glucocorticoid-induced osteoporosis treatment algorithm].
    Payer J; Killinger Z; Brázdilová K
    Vnitr Lek; 2009 May; 55(5):506-11. PubMed ID: 19514617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options.
    De Nijs RN
    Minerva Med; 2008 Feb; 99(1):23-43. PubMed ID: 18299694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Modifications of markers of bone resorption in patients affected by glucocorticoid induced osteoporosis (GIOP) treated with neridronate].
    Benucci M; Dolenti S; Saviola G; Manfredi M
    Recenti Prog Med; 2006 Jan; 97(1):24-7. PubMed ID: 16535926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone mineral density in male schizophrenia patients: a review.
    Meyer JM; Lehman D
    Ann Clin Psychiatry; 2006; 18(1):43-8. PubMed ID: 16517452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK; Weston R; Mistry R; Parr NJ
    BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sickle cell anaemia: is it a cause for secondary osteoporosis?
    Sadat-Ali M; Al Elq AH
    West Afr J Med; 2007; 26(2):134-7. PubMed ID: 17939316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of glucocorticoids on bone mineral density in patients with idiopathic thrombocytopenic purpura].
    Hasegawa M; Nisikawa M; Nomura S; Takubo T; Suehiro A; Saigo K; Hayashi K; Tamaki S; Mizutani M; Uemura Y; Kurata Y;
    Rinsho Ketsueki; 2005 Feb; 46(2):121-6. PubMed ID: 16447705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy.
    Bruder JM; Ma JZ; Basler JW; Welch MD
    Urology; 2006 Jan; 67(1):152-5. PubMed ID: 16413352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Barriers in the management of glucocorticoid-induced osteoporosis.
    Guzman-Clark JR; Fang MA; Sehl ME; Traylor L; Hahn TJ
    Arthritis Rheum; 2007 Feb; 57(1):140-6. PubMed ID: 17266078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of monoclonal gammopathy of undetermined significance/myeloma in patients with acute osteoporotic vertebral fractures.
    Golombick T; Diamond T
    Acta Haematol; 2008; 120(2):87-90. PubMed ID: 18852483
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.